CLNN Clene Inc
Price (delayed)
$3
Market cap
$25.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.67
Enterprise value
$34.39M
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new
Highlights
The company's debt fell by 35% YoY and by 9% QoQ
CLNN's quick ratio has soared by 92% from the previous quarter but it is down by 14% YoY
CLNN's EPS is up by 40% year-on-year but it is down by 5% since the previous quarter
The equity has plunged by 166% YoY and by 115% from the previous quarter
The gross profit has contracted by 49% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of CLNN
Market
Valuations
Earnings
Shares outstanding
8.59M
Market cap
$25.76M
Enterprise value
$34.39M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
100.55
Revenue
$342,000
Gross profit
$272,000
Operating income
-$33.09M
Net income
-$39.4M
EBIT
-$35.34M
EBITDA
-$33.17M
Free cash flow
-$21.34M
Per share
Balance sheet
Liquidity
EPS
-$5.67
EPS diluted
-$5.67
Free cash flow per share
-$3.07
Book value per share
-$1.11
Revenue per share
$0.05
TBVPS
$3.93
Total assets
$27.34M
Total liabilities
$36.19M
Debt
$20.84M
Equity
-$8.86M
Working capital
$5.87M
Debt to equity
-2.35
Current ratio
1.57
Quick ratio
1.19
Net debt/EBITDA
-0.26
Margins
Efficiency
Dividend
EBITDA margin
-9,698%
Gross margin
79.5%
Net margin
-11,520.5%
Operating margin
-9,676.3%
Return on assets
-109.2%
Return on equity
N/A
Return on invested capital
-149.9%
Return on capital employed
-207.3%
Return on sales
-10,332.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLNN stock price
How has the Clene stock price performed over time
Intraday
16.28%
1 week
-15.25%
1 month
-33.33%
1 year
-62.12%
YTD
-43.5%
QTD
-2.6%
Financial performance
How have Clene's revenue and profit performed over time
Revenue
$342,000
Gross profit
$272,000
Operating income
-$33.09M
Net income
-$39.4M
Gross margin
79.5%
Net margin
-11,520.5%
Clene's operating margin has plunged by 56% YoY and by 19% from the previous quarter
The company's net margin has shrunk by 52% YoY and by 35% QoQ
The gross profit has contracted by 49% YoY and by 18% from the previous quarter
The revenue fell by 48% YoY and by 19% QoQ
Growth
What is Clene's growth rate over time
Valuation
What is Clene stock price valuation
P/E
N/A
P/B
N/A
P/S
61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
100.55
CLNN's EPS is up by 40% year-on-year but it is down by 5% since the previous quarter
The equity has plunged by 166% YoY and by 115% from the previous quarter
The stock's price to sales (P/S) is 91% less than its 5-year quarterly average of 578.8 and 43% less than its last 4 quarters average of 92.8
The revenue fell by 48% YoY and by 19% QoQ
Efficiency
How efficient is Clene business performance
CLNN's return on sales has dropped by 50% year-on-year and by 39% since the previous quarter
The ROA has contracted by 28% from the previous quarter and by 22% YoY
Clene's return on invested capital has decreased by 22% YoY and by 18% QoQ
Dividends
What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLNN.
Financial health
How did Clene financials performed over time
The total assets is 24% smaller than the total liabilities
CLNN's quick ratio has soared by 92% from the previous quarter but it is down by 14% YoY
The company's current ratio has surged by 89% QoQ and by 2.6% YoY
Clene's debt to equity has shrunk by 198% YoY but it has surged by 58% QoQ
The equity has plunged by 166% YoY and by 115% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.